perenostobart (SRF617) / Coherus Oncology - LARVOL DELTA

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=16 | Terminated | Sponsor: Coherus Biosciences, Inc. | Completed ➔ Terminated; The study was terminated for strategic reasons, not due to any safety concerns.

Combination therapy • Metastases • Trial termination • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=85 | Completed | Sponsor: Surface Oncology | Active, not recruiting ➔ Completed | N=177 ➔ 85

Enrollment change • Metastases • Trial completion • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ENTPD1 • HER-2 • PD-L1

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023 (GlobeNewswire) - "Research and development (R&D) expenses were $13.8 million for the second quarter ended June 30, 2023, compared to $18.2 million for the same period in 2022. This decrease was primarily driven by a reduction in manufacturing costs for our SRF388 program and the strategic decision to pause the SRF617 program as part of our corporate restructuring in November 2022. R&D expenses included $0.4 million in stock-based compensation expense for the second quarter ended June 30, 2023."

Commercial • Oncology • Solid Tumor

New Funding Awards February 2023 (Duke University School of Medicine) - "Harry Erba of Cell Therapy has received an award from Aptose Biosciences Inc. for a project entitled 'HM-FLTI-101.' Total funding will be $1,289,825. Harry Erba of Cell Therapy has received an award from MacroGenics, Inc. for a project entitled 'MacroGenics MGD024-01: A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies.' Total funding will be $1,036,935....Daniel George of Oncology has received an award from Surface Oncology for a project entitled 'Surf-617: SRF617 + Etrumadenant + Zimberelimab for mCRPC.' Total funding will be $26,860. Christopher Hoimes of Oncology has received an award from Synthekine for a project entitled "Synthekine STK-012." Total funding will be $726,110."

Announcement

SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties. (PubMed, Immunohorizons) - "Syngeneic tumor studies using human CD39 knock-in mice show that SRF617 can modulate CD39 levels on immune cells in vivo and can penetrate the TME of an orthotopic tumor, leading to increased CD8+ T-cell infiltration. Targeting CD39 is an attractive approach for treating cancer, and, as such, the properties of SRF617 make it an excellent drug development candidate."

Immunomodulating • Journal • Immune Modulation • Oncology • CD8 • ENTPD1 • IL18 • IL1B

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=15 | Completed | Sponsor: Surface Oncology | Active, not recruiting ➔ Completed | N=40 ➔ 15

Combination therapy • Enrollment change • Metastases • Trial completion • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo (SITC 2021) - P1 | "Wild-type mice bearing subcutaneous (s.c.) KPC1245 tumors were treated with anti-murine CD39 antibody, alone or in combination with gemcitabine. These studies demonstrate the therapeutic potential of targeting CD39 for the treatment of cancer. SRF617 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors (NCT04336098) and in combination with chemotherapy in patients with pancreatic cancer."

Preclinical • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • CD73 • CD8 • ENTPD1 • NT5E

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: Surface Oncology | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2023 ➔ Jul 2023 | Trial primary completion date: Nov 2023 ➔ May 2023

Combination therapy • Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CAST

KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=177 | Active, not recruiting | Sponsor: Surface Oncology | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2022 ➔ Oct 2023 | Trial primary completion date: Oct 2022 ➔ Aug 2023

Enrollment closed • Trial completion date • Trial primary completion date • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ENTPD1 • HER-2 • PD-L1

"Ah, here we go. SRF617 at #Esmo21. Could explain $SURF's decision to halt!" (@JacobPlieth)

Oncology

First-in-human phase 1 trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors. (ESMO-IO 2021) - P1 | "Methods Pts with advanced solid tumors were enrolled in a phase 1 dose-escalation study of SRF617 (NCT04336098) to establish preliminary safety as monotherapy as well as in combination with gemcitabine + nab-paclitaxel (GA) or pembrolizumab (P) and to identify doses suitable for monotherapy and combination expansion cohorts...Legal entity responsible for the study Surface Oncology, Cambridge, MA, USA. Funding Surface Oncology, Cambridge, MA, USA."

Clinical • Monotherapy • P1 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ENTPD1

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort (GlobeNewswire) - "SRF617, novel antibody targeting CD39: Following a portfolio review, Surface made the strategic decision to pause the internal clinical development of SRF617, a novel antibody targeting CD39. In conjunction with this change, Surface is implementing an organizational restructuring that will result in a reduction of approximately 20% of its workforce; This change will enable the company to focus its resources on the advancement of SRF388 and SRF114, which Surface believes hold the greatest near-term potential to provide benefit to patients and drive value for shareholders. Management now projects that current cash and cash equivalents are sufficient to fund Surface into the second quarter of 2024....SRF114, potential best-in-class antibody targeting CCR8: In October, the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for SRF114, a potential best-in-class CCR8 inhibitor. Surface expects to enroll the first patient soon."

Discontinued • IND • New trial • Oncology

"$SURF "pausing" development of SRF617 (anti-CD39 MAb), relevant for Tizona $ABBV (TTX-030), $IPH $AZN (IPH5201) & $GILD $RCUS (AB598)" (@JacobPlieth)

ENTPD1

Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022 (GlobeNewswire) - "Surface Oncology...reported financial results and business highlights for the second quarter of 2022 as well as upcoming anticipated corporate milestones....Research and development (R&D) expenses were $18.2 million for the second quarter ended June 30, 2022, compared to $12.7 million for the same period in 2021. This increase was primarily driven by progress on our SRF617 and SRF388 Phase 1 and Phase 2 clinical trials."

Commercial • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Surface Oncology | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

"$SURF update on SRF617, a fully human antibody designed to inhibit CD39 in 2H'22. Raised $21M in Q1 via ATM. Cash, cash equivalents $150M" (@BioStocks)

ENTPD1

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021 (GlobeNewswire) - "Surface will present new translational data on SRF388 at the American Association for Cancer Research (AACR) Annual Meeting in April 2022. In addition, the company anticipates presenting updated clinical data from SRF388 in the second quarter of 2022. Clinical data update for SRF617 is expected in the second half of 2022."

Clinical data • Oncology

SRF617-101: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=177 | Recruiting | Sponsor: Surface Oncology | N=100 ➔ 177

Enrollment change • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ENTPD1 • HER-2 • PD-L1

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: Surface Oncology

Clinical • Combination therapy • New P2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 (GlobeNewswire) - P1, N=100; NCT04336098; Sponsor: Surface Oncology; "Ten of 32 evaluable patients (31%) receiving SRF617 as a monotherapy had disease stabilization at eight weeks, with four (12%) persisting beyond 16 weeks. One patient with NSCLC whose disease previously progressed on chemotherapy and PD-1 blockade had prolonged disease stabilization beyond 24 weeks...Of patients treated with SRF617 in combination with pembrolizumab (KEYTRADA®), four of eight evaluable patients (50%) had disease stabilization at six weeks, with three of the eight exhibiting disease control at 12 weeks and one beyond 20 weeks. Of patients treated with SRF617 in combination with gemcitabine/albumin-bound paclitaxel (Abraxane®), there was one confirmed partial response in a patient with pancreatic cancer whose disease had progressed on prior chemotherapy."

P1 data • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 (GlobeNewswire) - "Surface Oncology...announced that a poster presentation sharing new clinical data from the ongoing SRF617 Phase 1 trial will be presented at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021, to be held virtually from December 8 to 11, 2021. The poster includes new data from the ongoing Phase 1 study of SRF617, an antibody targeting CD39, as both a monotherapy and in combination, in patients with advanced solid tumors."

P1 data • Oncology • Solid Tumor

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021 (GlobeNewswire) - "Investigational New Drug (IND) filing for GSK4381562, formerly SRF813, targeting the PVRIG checkpoint and partnered with GlaxoSmithKline, will be filed in Q4 2021.; Data update for SRF617 anticipated at the European Society for Medical Oncology Immuno-Oncology Congress taking place December 8-11, 2021.; Data update for SRF388 anticipated in early 2022."

IND • P1 data • Clear Cell Renal Cell Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting (GlobeNewswire) - "SRF617 Highlights: In combination with gemcitabine, anti-CD39 therapy promotes an increase in tumor macrophages while reducing CD39 expression and activity; SRF388 Highlights: IL-27 induces robust gene expression in human immune cells and cancer cell lines that include several inhibitory receptors and canonical interferon-regulated genes."

Preclinical • Oncology

Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting (GlobeNewswire) - "Surface Oncology...announced that scientific posters sharing preclinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, to be held virtually and at the Walter E. Washington Convention Center in Washington, D.C. November 10-14, 2021. The posters include preclinical data from Surface Oncology’s two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27), both of which are in Phase 1 clinical studies. Surface scientists will be in attendance on-site in Washington D.C. to present the data."

Preclinical • Oncology

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021 (GlobeNewswire) - "Selected Anticipated Near-term Corporate Milestones: Investigational New Drug (IND) filing for GSK4381562 formerly, SRF813, targeting the PVRIG checkpoint and partnered with GlaxoSmithKline, anticipated in 2H 2021. Data update from Phase 1 study of SRF617 anticipated in late 2021. Data update from Phase 1 study of SRF388 anticipated in early 2022."

IND • P1 data • Oncology • Solid Tumor